U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H12N2O8.C4H10N2.Ca.2H
Molecular Weight 416.44
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIPERAZINE CALCIUM EDETATE

SMILES

[H+].[H+].[Ca++].C1CNCCN1.[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O

InChI

InChIKey=ROJMAHHOFDIQTI-UHFFFAOYSA-L
InChI=1S/C10H16N2O8.C4H10N2.Ca/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;1-2-6-4-3-5-1;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);5-6H,1-4H2;/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H
Molecular Weight 1.0079
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C10H12N2O8
Molecular Weight 288.2109
Charge -4
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H10N2
Molecular Weight 86.1356
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details

Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Hypocalcemia, chronic (treatment) ā€” Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred
PubMed

PubMed

TitleDatePubMed
Studies on the calcemic effect of intravenous secretin in humans.
1975 Jun
Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein.
1999 Nov
Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V.
2000 Feb 11
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors.
2000 Feb 15
Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors.
2000 Nov
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.
2000 Nov 10
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement.
2000 Oct 15
Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.
2001 Aug 28
[Acute renal failure caused by hypercalcemia].
2001 Jun 10
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.
2001 Jun 8
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.
2001 Sep
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.
2001 Sep
Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore.
2001 Sep 1
A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein.
2001 Sep 15
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells.
2002 Apr 19
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells.
2002 Feb
Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3.
2002 Feb 1
Expression of functional CCR and CXCR chemokine receptors in podocytes.
2002 Jun 15
Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart.
2002 Mar
Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity.
2009 Jul-Aug
A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans.
2012 Apr
Effect of calcium phosphate and vitamin Dā‚ƒ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron.
2014 Jan 17
Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review.
2014 Jul
Effects of ultrasound treatment on physico-chemical, functional properties and antioxidant activity of whey protein isolate in the presence of calcium lactate.
2018 Mar
Patents

Sample Use Guides

oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid). inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:04:13 GMT 2023
Edited
by admin
on Fri Dec 15 15:04:13 GMT 2023
Record UNII
L4QEN8344Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIPERAZINE CALCIUM EDETATE
INN  
INN  
Official Name English
PIPERAZINE EDETATE CALCIUM [MI]
Common Name English
PIPERAZINE CALCIUM EDATHAMIL
Common Name English
PERIN
Brand Name English
PIPERAZINE EDETATE CALCIUM [USAN]
Common Name English
piperazine calcium edetate [INN]
Common Name English
MONOCALCIUM MONOPIPERAZINIUMETHYLENEDIAMINE TETRAACETATE
Common Name English
CALCIATE(2-), ((N,N'-1,2-ETHANEDIYLBIS(N-(CARBOXYMETHYL)GLYCINATO))(4-)-N,N',O,O',ON,ON')-, (OC-6-21)-, DIHYDROGEN, COMPD. WITH PIPERAZINE (1:1)
Common Name English
JUSTELMIN
Brand Name English
PIPERAZINE EDETATE CALCIUM
MI   USAN  
USAN  
Official Name English
Code System Code Type Description
EVMPD
SUB09869MIG
Created by admin on Fri Dec 15 15:04:13 GMT 2023 , Edited by admin on Fri Dec 15 15:04:13 GMT 2023
PRIMARY
NCI_THESAURUS
C175844
Created by admin on Fri Dec 15 15:04:13 GMT 2023 , Edited by admin on Fri Dec 15 15:04:13 GMT 2023
PRIMARY
ChEMBL
CHEMBL2106963
Created by admin on Fri Dec 15 15:04:13 GMT 2023 , Edited by admin on Fri Dec 15 15:04:13 GMT 2023
PRIMARY
MERCK INDEX
m8846
Created by admin on Fri Dec 15 15:04:13 GMT 2023 , Edited by admin on Fri Dec 15 15:04:13 GMT 2023
PRIMARY Merck Index
FDA UNII
L4QEN8344Z
Created by admin on Fri Dec 15 15:04:13 GMT 2023 , Edited by admin on Fri Dec 15 15:04:13 GMT 2023
PRIMARY
CAS
122-50-9
Created by admin on Fri Dec 15 15:04:13 GMT 2023 , Edited by admin on Fri Dec 15 15:04:13 GMT 2023
SUPERSEDED
CAS
12002-30-1
Created by admin on Fri Dec 15 15:04:13 GMT 2023 , Edited by admin on Fri Dec 15 15:04:13 GMT 2023
PRIMARY
SMS_ID
100000081965
Created by admin on Fri Dec 15 15:04:13 GMT 2023 , Edited by admin on Fri Dec 15 15:04:13 GMT 2023
PRIMARY
PUBCHEM
31213
Created by admin on Fri Dec 15 15:04:13 GMT 2023 , Edited by admin on Fri Dec 15 15:04:13 GMT 2023
PRIMARY
INN
580
Created by admin on Fri Dec 15 15:04:13 GMT 2023 , Edited by admin on Fri Dec 15 15:04:13 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY
ACTIVE MOIETY